Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns

George Sgouros, Yuni K. Dewaraja, Freddy Escorcia, Stephen A. Graves, Thomas A. Hope, Amir Iravani, Neeta Pandit-Taskar, Babak Saboury, Sara St James, Pat B. Zanzonico

Research output: Contribution to journalArticlepeer-review


Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose-versus-response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.

Original languageEnglish (US)
Pages (from-to)12S-22S
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
StatePublished - Dec 1 2021


  • dosimetry
  • imaging
  • radionuclide therapy
  • radiopharmaceutical therapy
  • radiopharmaceuticals
  • theranostics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns'. Together they form a unique fingerprint.

Cite this